PAEDIATRIC ENDOCRINOLOGY Treatment of girls with central precocious puberty

摘要

Gonadotropin-releasing hormone analogues (GnRHa) can improve adult height prospects in children with central precocious puberty (CPP). A recent report demonstrates that 50 mg histrelin subcutaneous implants are safe and effective when used yearly. However, questions remain regarding the use of GnRHa in girls with idiopathic CPP, who experience a slow progressive form of puberty.